mayoly spindler
Mayoly Spindler is a French, family-owned independent pharmaceutical laboratory founded in 1909, specializing in gastroenterology and dermocosmetics, and serving patients and consumers through pharmacy channels in over 100 countries with brands such as Smecta, Meteospasmyl, Topicrem, and Probiolog.
- Company typePrivate
- Founded1909
- HeadquartersChatou, France
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What mayoly spindler does
Mayoly Spindler is a French, family-owned and independent pharmaceutical laboratory founded in 1909, specializing in gastroenterology and dermocosmetics. The group operates across five business units — Consumer Healthcare (OTC), Pharma (prescription), Dermocosmetics, Diagnostic, and Production — with a portfolio of heritage brands including Smecta (clay-based gastrointestinal therapy), Meteospasmyl, Probiolog (probiotics), Topicrem (sensitive-skin skincare), BeauTerra (natural cosmetics), Kersiens (micronutrition), and Colchicine.
The company manufactures in five GMP-certified production facilities, four of which are in France (Rueil-Malmaison HQ, Dammarie-les-Lys, L'Isle-sur-la-Sorgue, Dreux, Auxerre), with proprietary expertise in natural clay transformation for Smecta's active ingredient and in probiotic and dietary supplement formulation. Certifications span ISO 22716, GxP, 21 CFR Part 11, and GAMP 5.
Mayoly generates revenue through prescription and OTC pharmaceutical sales, consumer health products, dermocosmetics, in-vitro diagnostics, and third-party contract manufacturing. Distribution is primarily B2B through pharmacy channels — a French field sales force (Délégués Pharmaceutiques) covering independent pharmacies and chains, supplemented by wholesalers and a network of subsidiaries and exclusive distributors in more than 100 countries. Roughly 65% of revenue is international. Disclosed revenue exceeded €500 million in 2022 following the integration of Ipsen's Family Health business and the acquisition of Pharm Nature, with a publicly stated target of over €600 million by 2027. Headcount stands at approximately 2,200 globally.
mayoly spindler firmographics
Firmographics- Name
- mayoly spindler
- Legal name
- MAYOLY
- Website
- https://mayoly.com
- Company type
- Private
- Founded year
- 1909
- Operating status
- Operating
- Short description
- Mayoly Spindler is a French, family-owned independent pharmaceutical laboratory founded in 1909, specializing in gastroenterology and dermocosmetics, and serving patients and consumers through pharmacy channels in over 100 countries with brands such as Smecta, Meteospasmyl, Topicrem, and Probiolog.
- Ownership category
- akta.pro rank
mayoly spindler industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
- akta.pro secondary industries
- Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Probiotics & Digestive Health Supplements (CRADAGAF)
Keywords
Where mayoly spindler is headquartered
LocationHeadquarters
- HQ city
- Chatou
- HQ country
- France
- HQ region
- Europe
Offices5 records
Markets served
mayoly spindler business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical products (Rx & OTC): Prescription and over-the-counter pharmaceutical products primarily in gastroenterology, including gastrointestinal medicines such as Meteospasmyl and colchicine-based treatments. Revenue from direct sales to pharmacies and hospital procurement.
- Consumer Healthcare / OTC: Consumer health products sold over-the-counter in pharmacies, including digestive health supplements, dermocosmetics, and nutritional supplements under brands such as Probiolog, Topicrem, and BeauTerra.
- Contract Manufacturing / Production: Manufacturing services for third-party pharmaceutical and health products through Mayoly's network of 5 GMP-certified production facilities in France, serving both the group's own portfolio and external clients.
- Diagnostic products: In-vitro diagnostic products distributed internationally through export channels and partnerships.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | No public pricing tiers disclosed |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
mayoly spindler product offering
Product offeringCore offering
Mayoly Spindler is a French family-owned pharmaceutical laboratory that develops, manufactures, and markets prescription and over-the-counter drugs, probiotics, dermocosmetic skincare, and in-vitro diagnostics, with core specialization in gastroenterology and dermocosmetics. The company sells products such as Meteospasmyl, Smecta, Probiolog, Colchicine, and Topicrem under established brands across 100+ countries, operating five GMP-certified manufacturing facilities (four in France).
Product overview
Mayoly Spindler is a French, family-owned, independent pharmaceutical laboratory with over 100 years of expertise. The company operates across five business units: Consumer HealthCare (OTC products), Pharma (prescription medications), Dermocosmetics (skincare brands including Topicrem and BeauTerra), Diagnostic (in vitro diagnostics), and Production (manufacturing with 5 factories in France). Key products include Meteospasmyl (gastrointestinal), Probiolog (probiotics), Smecta (clay-based therapy), Colchicine (strategic medication), and Kersiens (micronutrition). The company generated over 500M€ revenue in 2022 with 65% international sales across more than 100 countries, targeting 600M€ by 2027.
Differentiator
Problem solved
Functional benefit
Brands
- BeauTerra: Natural and sensory cosmetics brand, manufactured in France, sold in pharmacies. Positioned among leaders in hygiene products in pharmacies with strong growth dynamics.
- Kersiëns
- Topicrem
- Probiolog
- Smecta
Products and services
- Meteospasmyl Prescription gastrointestinal medication for digestive disorders, bloating, and intestinal discomfort, supplied to pharmacies and hospitals.
- Smecta Clay-based therapeutic medication (using natural argile thérapeutique) for gastrointestinal disorders, manufactured at the L'Isle-sur-la-Sorgue GMP site.
- Colchicine Strategic essential medication produced domestically in partnership with GALIEN for patients requiring colchicine treatment.
- Probiolog Probiotic supplement range covering adult, child, and infant indications for gastrointestinal health and gut microbiota balance, sold in pharmacies.
- Topicrem Dermo-cosmetic skincare brand developed for sensitive skin and dermatological conditions, sold in pharmacies to consumers and recommended by healthcare professionals.
- BeauTerra Natural and sensory cosmetics brand manufactured in France and sold in pharmacies, positioned among leaders in pharmacy hygiene products.
- Kersiens
Quantifiable outcome
- Revenue exceeded €500M in 2022 following Ipsen CHC acquisition
- +2 more outcomes
Companies that use mayoly spindler
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
mayoly spindler technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
mayoly spindler partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- GALIENcoreMAYOLY and GALIEN partnered to relocate colchicine pharmaceutical production to Auxerre, France, strengthening French pharmaceutical sovereignty. This strategic partnership involves domestic production of a strategically essential medication for patients.
- Pierre-Louis Attwell / IMOCA RESILIENTcoreMAYOLY partnered with skipper Pierre-Louis Attwell and his IMOCA RESILIENT yacht for the Vendée Globe 2028, Mayoly's first participation in the legendary ocean race. The partnership, engaged since 2016, reflects shared values of entrepreneurship, ambition, authenticity, and challenge. The RESILIENT name symbolizes the ability to transform obstacles into momentum.
- IpsencoreMAYOLY acquired Ipsen's Family Health (Santé Familiale) business in July 2022, significantly expanding its consumer health portfolio. This major acquisition contributed to revenue exceeding €500M in 2022 and strengthened Mayoly's position in the French consumer health market.
- Pharm NaturecoreMAYOLY acquired Pharm Nature in June 2022, finalizing the acquisition in September 2022. This acquisition strengthened Mayoly's position in the dietary supplement (compléments alimentaires) market, complementing its existing probiotic (Probiolog) portfolio.
- AzurRx BiopharmaminorMAYOLY restructured its R&D partnership with US-based AzurRx Biopharma (NASDAQ:AZRX) in April 2019 regarding the MS1819 project. The restructuring modified the terms of collaboration on this gastrointestinal drug development program.
- afa Crohn RCHminorMAYOLY supported the 'Vogue avec un Crohn' project in partnership with afa Crohn RCH (patient association), raising awareness about Crohn's disease. The initiative included sailing challenges and public engagement campaigns supported by Mayoly Spindler and MSD France.
- Hôpital Necker-Enfants malades AP-HPminorTopicrem, Mayoly's dermocosmetic brand, has been committed for over a year to Hôpital Necker-Enfants malades AP-HP through the therapeutic well-being space 'Les Miroirs Complices', supporting children and adolescents with dermatological conditions through psychological, psychomotor, socio-aesthetic, and sophrology workshops.
Scale indicators9 records
Recent moves9 records
Expansion highlights5 records
mayoly spindler competitors and assessment
Company assessmentDirect peers
- Bouchara-Recordati: French subsidiary of Recordati specializing in pharma and consumer health products distributed via French pharmacy networks. Comparable in product mix and pharmacy-channel GTM.
- Faes Farma: Spanish pharma and consumer health company with OTC and prescription GI/skin products distributed through pharmacy channels. Closely comparable mid-cap European specialty pharma + consumer health model.
- Laboratoires Urgo: French family-owned healthcare company active in wound care, dermocosmetics, and consumer health sold through pharmacy channels. Closely comparable in ownership structure, French base, and pharmacy-led GTM motion.
- Galderma: Global pure-play dermatology and dermocosmetics company. Directly comparable on the dermocosmetics and sensitive-skin therapeutic skincare side of Mayoly's portfolio, particularly the Topicrem brand franchise.
- Stada Arzneimittel: European mid-cap specialty pharma and consumer health company with strong OTC and generics presence across European pharmacy channels. Comparable to Mayoly in scale (~€3–4B revenue), pharmacy-led GTM, and diversified pharma/consumer health mix.
- Pierre Fabre: French family-owned pharmaceutical and dermo-cosmetic laboratory with a similar portfolio split between prescription pharma, OTC consumer health, and pharmacy-channel dermocosmetics — a structural twin to Mayoly's five-business-unit model.
- Ipsen: French specialty pharmaceutical company historically focused on gastroenterology and consumer health. Direct peer given shared French base, GI franchise overlap (Mayoly acquired Ipsen's Family Health business in 2022), and similar specialty-pharma positioning.
Broad incumbents
- Perrigo: Global consumer self-care company (OTC, skincare, digestive health) with strong European pharmacy presence. Comparable across consumer health categories and OTC distribution model, though operating at significantly larger scale.
- Bayer Consumer Health: Division of Bayer focused on OTC and consumer health including digestive health (e.g., Iberogast). A broad incumbent competing with Mayoly in European pharmacy channels for GI and women's health OTC.
- Sanofi (Consumer Healthcare): Global pharmaceutical incumbent with a sizable Consumer Healthcare business including digestive health and dermocosmetics brands. Overlaps with Mayoly across OTC GI and pharmacy skincare but at materially greater scale and with broader geographic reach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
mayoly spindler social profiles
Digital presencemayoly spindler compliance and trust
Trust signalCompliance4 records
mayoly spindler financial estimates
Financial estimateRevenue estimate
Valuation estimate
mayoly spindler leadership team
Management profileNumber of profiles
Profiles1 record
mayoly spindler subsidiaries and ownership
Company hierarchySubsidiaries3 records
mayoly spindler funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
mayoly spindler M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about mayoly spindler
What does mayoly spindler do?
Mayoly Spindler is a French family-owned pharmaceutical laboratory that develops, manufactures, and markets prescription and over-the-counter drugs, probiotics, dermocosmetic skincare, and in-vitro diagnostics, with core specialization in gastroenterology and dermocosmetics. The company sells products such as Meteospasmyl, Smecta, Probiolog, Colchicine, and Topicrem under established brands across 100+ countries, operating five GMP-certified manufacturing facilities (four in France).
Is mayoly spindler a public or private company?
mayoly spindler is a private company. It is classified as family owned and is currently operating.
When was mayoly spindler founded?
mayoly spindler was founded in 1909.
Where is mayoly spindler based?
mayoly spindler is headquartered in Chatou, France, in the Europe region.
How does mayoly spindler make money?
Four revenue lines are on record. Pharmaceutical products (Rx & OTC) is the primary driver. The others are consumer Healthcare / OTC, contract Manufacturing / Production and diagnostic products.
Who are mayoly spindler's main competitors?
Direct peers on record are Bouchara-Recordati, Faes Farma, Laboratoires Urgo, Galderma, Stada Arzneimittel, Pierre Fabre and Ipsen. Broad incumbents are Perrigo, Bayer Consumer Health and Sanofi (Consumer Healthcare).
Does mayoly spindler have an API?
No public API is recorded for mayoly spindler.
What industry is mayoly spindler in?
mayoly spindler's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of CRABAAAF, Dermocosmetics & Medical-Grade Skincare. Its NAICS code is 325412 and its SIC code is 5122.